Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

A user with PCOS experienced hair loss and found success using a triple dose of O.N.E Omega by Pure Encapsulations after discovering low Omega fatty acids. Biotin provided minimal improvement, but the Omega supplement significantly restored hair.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

A user reported full recovery from Post Finasteride Syndrome after 6 months of HCG treatment. They used 250IU of HCG three times a week.

The conversation discusses switching from oral to topical finasteride due to side effects like nipple soreness. The user seeks advice on diluting and applying topical finasteride to minimize adverse effects.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

A satirical post jokes about a user meeting a doctor at the zoo who praises finasteride (Fin) for hair loss treatment, claiming it has a low side-effect profile and is effective. Replies include humorous disbelief, comparisons to other risks, and some personal accounts of side effects from Fin.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

Finasteride and minoxidil are commonly recommended by hair transplant clinics, including those in Turkey, despite some negative perceptions and concerns about side effects. The conversation highlights differing opinions on the effectiveness and safety of these treatments, with some users expressing skepticism about side effects and others emphasizing the importance of these medications for successful hair transplants.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The user is experiencing severe hair loss and color change despite low testosterone levels and healthy lifestyle changes. They have tried ketoconazole shampoo and consulted a dermatologist, who found no scalp issues but suggested using Toppik for coverage.